Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Background/Aims Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulce...

Full description

Bibliographic Details

Published in:	Intestinal Research
Main Authors:	Robert Gilmore, Richard Fernandes, Imogen Hartley, Arteen Arzivian, Rupert Leong, Bridgette Andrew, Abhinav Vasudevan, Tessa Greeve, Gregory Thomas Moore, Steven Kim, Daniel Lightowler, Abhey Singh, Gillian Mahy, Aditya Mithanthaya, Kannan Venugopaul, Sangwoo Han, Robert Bryant, Jack West, Jonathan Segal, Britt Christensen, Crispin Corte, Nik Ding, Yoon-Kyo An, Jakob Begun
Format:	Article
Language:	English
Published:	Korean Association for the Study of Intestinal Diseases 2025-07-01
Subjects:	ulcerative colitis upadacitinib janus kinase inhibitors tofacitinib intestinal ultrasound
Online Access:	http://irjournal.org/upload/pdf/ir-2024-00127.pdf